B'

across the blood brain barrier in said mammal and stabilizers/surfactants which allow a release of said physiologically effective substance(s) from said nanoparticles and a passage of said substance(s) across the blood brain barrier separate from the nanoparticles. It is furthermore preferred that said stabilizer/surfactant comprises a substance selected from the group consisting of polysorbates, dextrans, carboxylic acid esters of multifunctional alcohols, polyoxamers, polyoxamines, alkoxylated ethers, alkoxylated esters, alkoxylated mono-, di and triglycerides, alkoxylated phenols and diphenols, substances of the Genapol<sup>R</sup> and Bauki<sup>R</sup> series, metal salts of carboxylic acids, metal salts of alcohol sulfates and metal salts of sulfosuccinates and mixtures of two or more of said substances, wherein said Genapol<sup>R</sup> substances are of the formula

$$CH_3(CH_2)_y$$
 -  $(O-CH_2-CH_2)_x$ -OH

wherein y is in the range of 4 to 18 and x is in the range of 1 to 18, and said Bauki<sup>R</sup> substances are of the formulas (I) or (I')

in which  $R_1$ ,  $R_2$ ,  $R_5$  and  $R_6$  are identical or different and represent hydrogen and a methyl or ethyl group,

Q represents a valency, oxygen or an ester or amide bridge and Q' denotes hydrogen if Q represents a valency or oxygen, and is a hydroxyl or amino group if Q represents an ester or amide bridge,